SCHEMBL24322652

SCHEMBL24322652

O=C(NC[C@H]1CCCN1)C(=O)NC1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
MAPT P10636 2/20 0.42
GAA P10253 1/20 0.41
FPR3 P25089 2/20 0.39
FPR2 P25090 2/20 0.39
IKBKB O14920 2/20 0.37
DRD2 P14416 2/20 0.37
DRD3 P35462 2/20 0.37
FDPS P14324 1/20 0.36
CYP2D6 P10635 2/20 0.35
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
TP53 P04637 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
TSHR P16473 1/20 0.35
MLNR O43193 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24323660 0.95 SMN1; SMN2 (0.50) SMN1; SMN2RAB9ANPC1MAPTGAA
SCHEMBL24323644 0.94 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1MAPTGAA
SCHEMBL23201076 0.81 DRD2 (0.39) SMN1; SMN2MAPTFPR3FPR2IKBKB
SCHEMBL23201079 0.81 DRD2 (0.39) SMN1; SMN2MAPTFPR3FPR2IKBKB
SCHEMBL24322789 0.80 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1MAPTGAA
SCHEMBL2937827 0.77 CYP2D6 (0.42) SMN1; SMN2MAPTFPR3FPR2IKBKB
SCHEMBL14919306 0.77 CYP2D6 (0.42) SMN1; SMN2MAPTFPR3FPR2IKBKB
SCHEMBL3335001 0.77 CYP2D6 (0.42) SMN1; SMN2MAPTFPR3FPR2IKBKB
SCHEMBL28532872 0.77 DRD2 (0.44) SMN1; SMN2FPR3FPR2IKBKBDRD2
SCHEMBL28532873 0.77 DRD2 (0.44) SMN1; SMN2FPR3FPR2IKBKBDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof Psomagen Inc. (US) 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof HTRA1, GIPR, HPN SMN1; SMN2 4226/4885RAB9A 435/4885NPC1 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.